308 Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma
Main Authors: | Dirk Schadendorf, Mark Middleton, Jeffrey Weber, Delphine Hennicken, Paolo Ascierto, Andriy Moshyk, Roberto Zoffoli, Anne Pieters, Adenike Amadi, Katrin Kupas, Srividya Kotapati |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma
by: Hemstock, M, et al.
Published: (2020) -
Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
by: Wolfram Samlowski, et al.
Published: (2023-02-01) -
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
by: Dirk Schadendorf, et al.
Published: (2022-12-01) -
Effective treatment of gallbladder neuroendocrine carcinoma with nivolumab
by: Shinichiro Kanda, et al.
Published: (2023-10-01) -
Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma
by: M. N. Khagazheeva, et al.
Published: (2022-06-01)